🧬 Endocrinology Update: Liraglutide Approved, AI Predicts T1D Risk, Sogroya Backed by NICE and More
Dive into this week’s Endocrinology Updates, where we cover the most impactful developments across diabetes care, growth disorders and AI-powered diagnostics.
📌 In This Episode:
✔️ Biocon’s liraglutide approved in India for treating Type 2 diabetes in patients aged 10 and above under the CDSCO’s new global-aligned pathway
✔️ Pediatric Type 2 diabetes remains drastically underdiagnosed—potentially ten times more common than reported, urging urgent screening reform
✔️ NICE recommends Sogroya as a once-weekly growth hormone therapy for children aged 3–17
✔️ Mitoquinone, a CoQ10 analog, shows early promise in reversing heart failure caused by Type 2 diabetes, with a 15 percent improvement in cardiac efficiency
✔️ Sandoz launches WYOST and Jubbonti, the first interchangeable Denosumab biosimilars in the U.S. for osteoporosis and cancer-related bone disease
✔️ Dapagliflozin proves dual benefit in managing Type 2 diabetes and MASH, improving liver health in over 50 percent of trial participants
✔️ AI tool DRS4C predicts Type 1 diabetes risk with precision using microRNA data, validated across nearly 6,000 samples worldwide
✔️ UVA’s digital twin artificial pancreas enhances Type 1 diabetes control, increasing time-in-range and reducing HbA1c through real-time simulation-based adjustments
📢 Stay Ahead in Endocrinology Research!
✅ Like, share, and subscribe for weekly updates on endocrinology, diabetes, PCOS, growth hormone, and more
#Endocrinology #DiabetesCare #PediatricDiabetes #GrowthHormone #Biosimilars #HeartFailure #Type2Diabetes #Type1Diabetes #AIinHealthcare #LiverHealth #DigitalTwin #LucidQuest #MedicalInnovation #HealthcareConsulting #ClinicalResearch